skip to Main Content

Chemo With or Without Veliparib Active in BRCA/PALB2+ Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The combination of gemcitabine plus cisplatin with or without veliparib is highly active in patients with pancreatic ductal adenocarcinoma (PDAC) and a germline BRCA/PALB2 mutation.

In a randomized, multinational phase II trial, both combinations exceeded the prespecified threshold for response rate, with higher rates of grade 3/4 hematologic toxicity observed with the triplet compared with the doublet, Eileen M. O’Reilly, MD, said at the 2020 Gastrointestinal Cancers Symposium. Read more . . .  


Back To Top